On September 6, 2022 Median Technologies (ALMDT) (Paris:ALMDT) reported that the Company will be participating in the 2022 ESMO (Free ESMO Whitepaper) (European Society for Medical Oncology) Congress, to be held in Paris, France, September 9-13 (venue: Paris Expo Porte de Versailles) (Press release, MEDIAN Technologies, SEP 6, 2022, View Source [SID1234619098]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will present two scientific posters. Details of the sessions include:

255P – Challenges to Assess Bone Metastases in Blinded Independent Central Review (BICR) of Breast Cancer Trials Using RECIST 1.1

Session: Breast Cancer, Metastatic
Date: Sep 10, 2022
Timeslot to meet the scientific team: 12:00 pm – 1:00 pm CEST
Place: Poster Area, Hall 4

919P – Artificial Intelligence Supporting Lung Cancer Screening: Computer Aided Diagnosis of Lung Lesions Driven by Morphological Feature Extraction

Session: New Diagnostic Tools
Date: Sep 11, 2022
Timeslot to meet the scientific team: 12:00 pm – 1:00 pm CEST
Place: Poster Area, Hall 4

During the industry exhibition, Median team will be available at booth #447, Hall 7.2 to discuss the scientific posters, present the latest developments on iBiopsy LCS CADe/CADx SaMD as well as the Company’s iCRO services for image management in oncology trials including Imaging Lab, intelligent imaging capabilities for drug development. Daily presentation sessions on Imaging Lab are planned at 3:00 pm CEST at booth.

More about the ESMO (Free ESMO Whitepaper) congress: View Source